Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 57

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study on Mecasermin Rinfabate for Preventing Chronic Lung Disease in Extremely Premature Babies

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Mecasermin Rinfabate
  • Sponsor:Ohb Neonatology Limited

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.